Timeline of key events in the development of Campath

Results from 58 MS patients indicate Campath-1H more effective in those who are less advanced in their disease.2002-01-01T00:00:00+0000This comes about after a meeting between Jeff Bulchalter, chief executive officer of Ilex Oncology and Compston.2002-01-01T00:00:00+0000Known as CAMMS223, this randomised control trial, which compares Campath-1H with interferon beta-1a, indicates Campath-1H is an effective treatment for MS.2002-01-01T00:00:00+0000Genzyme pays US1 billion for the acquisition.2004-04-01T00:00:00+0000The resulting company is Bayer Schering Pharma.2006-01-01T00:00:00+0000Positive results reported from 1,779 patients.2007-01-01T00:00:00+00002007-09-01T00:00:00+00002007-12-01T00:00:00+0000Genzyme gains the worldwide rights to Campath-1H from Bayer Schering Pharma.2009-01-01T00:00:00+0000Campath-1H shown to help lower the amount of immunosuppressant drugs taken by organ transplant patients. 2011-01-01T00:00:00+0000Granted by European regulatory authorities.2013-09-17T00:00:00+00002013-09-17T00:00:00+0000US patients start campaign to reverse FDA decision2013-12-27T00:00:00+00002014-04-04T00:00:00+0000Access restricted to patients through the Risk Evaluation and Mitigation Strategy2014-11-25T00:00:00+0000
Date Event People Places
2002Results from 58 MS patients indicate Campath-1H more effective in those who are less advanced in their disease.Compston, ColesCambridge University
2002Ilex Oncology agrees to raise funds to sponsor clinical trials for Campath-1H in MS patients.Compston, BuchalterIlex Oncology, Cambridge University
2002 - 2004Phase II trial tests Campath-1H for relapsing-remitting MS.Compston, ColesCambridge University, Ilex Oncology
1 Apr 2004Genzyme acquires Ilex Oncology.Genzyme, Ilex Oncology
2006Schering AG merges with BayerBayer, Schering AG
2007 - 2011Two phase III randomised control trials conducted with Campath-1H in patients with early MSCompston, ColesCambridge University, Ilex Oncology, Genzyme
September 2007FDA approved Campath-1H as first-line treatment for B-CLL 
December 2007Campath-1H granted European regulatory approval as first-line treatment for B-CLL. 
2009Genzyme buys rights to Campath-1H.Bayer Schering Pharma, Genzyme
2011Positive results from trials using Campath-1H for organ transplant patientsWaldmann, CalneCambridge University
September 2013Campath-1H gains marketing approval for the treatment of MS.Waldmann, Compston, ColesCambridge University
September 2013European Commission grants approval of Campath 1H (Lemtrada) for MS treatmentCompston, Coles, WaldmannCambridge University, Sanofi
December 2013FDA rejected approval of Lembrada for MS treatmentSanofi
April 2014British NICE recommends alemtuzumab (Lemtrada) as cost effective MS treatmentCompston, Coles, WaldmannCambridge University, Sanofi
November 2014FDA approved Lemtrada for relapsing MS who failed to respond to alternative treatmentsSanofi

2002

Results from 58 MS patients indicate Campath-1H more effective in those who are less advanced in their disease.

2002

Ilex Oncology agrees to raise funds to sponsor clinical trials for Campath-1H in MS patients.

2002 - 2004

Phase II trial tests Campath-1H for relapsing-remitting MS.

2002

Genzyme acquires Ilex Oncology.

2006

Schering AG merges with Bayer

2007 - 2011

Two phase III randomised control trials conducted with Campath-1H in patients with early MS

Sep 2007

FDA approved Campath-1H as first-line treatment for B-CLL

Dec 2007

Campath-1H granted European regulatory approval as first-line treatment for B-CLL.

2009

Genzyme buys rights to Campath-1H.

2011

Positive results from trials using Campath-1H for organ transplant patients

Sep 2013

Campath-1H gains marketing approval for the treatment of MS.

Sep 2013

European Commission grants approval of Campath 1H (Lemtrada) for MS treatment

Dec 2013

FDA rejected approval of Lembrada for MS treatment

Apr 2014

British NICE recommends alemtuzumab (Lemtrada) as cost effective MS treatment

Nov 2014

FDA approved Lemtrada for relapsing MS who failed to respond to alternative treatments